xCures
-
January 10, 2020
Using Real World Evidence to Show Initial Results of a Drug Combination in Pancreatic Cancer Patients
Lola Rahib, PhDIn collaboration with xCures and the Huntsman Cancer Institute at the University of Utah, Cancer Commons presented initial findings from our real-world data registry on a novel treatment combination for pancreatic cancer patients at a conference in San Diego, CA, today. The “Special Conference on Advancing Precision Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies” is hosted by the… Read more »
-
March 6, 2019
Cancer Commons and xCures Invite Participation from Patients Who Try New Combo Therapy for Pancreatic Cancer
Treatment for metastatic pancreatic cancer has seen progress in recent years, but outcomes remain poor and treatment advances that can prolong patients’ lives, even for a few months, are eagerly awaited. Two papers published today in the scientific journal Nature Medicine report that a new combination of two drugs that are FDA-approved for other conditions may significantly delay progression of pancreatic cancer in cells… Read more »
-
September 6, 2018
Patient Foundation Collaboration to Advance ONC201 in DIPG and other H3 K27M-mutant Gliomas
Musella Foundation, Cancer Commons, xCures and Oncoceutics announced the initiation of a collaboration to develop ONC201 as a new treatment for diffuse intrinsic pontine glioma (DIPG) and other H3 K27M-mutant gliomas. Critical to the collaboration is $1M in funding from The Musella Foundation, Michael Mosier Defeat DIPG Foundation and The Cure Starts Now Foundation. Cancer Commons and xCures will contribute additional resources to the… Read more »